CAR-T Therapy for Refractory Autoimmune Diseases

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions

Autoimmune Diseases

Interventions

DRUG

JY231 (JY231 injection)

JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion.

Trial Locations (1)

Wuhan No.1 Hospital, Wuhan

All Listed Sponsors

lead

LiangZou

INDUSTRY

NCT07059169 - CAR-T Therapy for Refractory Autoimmune Diseases | Biotech Hunter | Biotech Hunter